Abstracts tagged "osteoporosis"

Abstract Number: 2319 • 2018 ACR/ARHP Annual Meeting
Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
Patrick Webster¹ and Tarun S. Sharma², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) is an under-recognized and under-treated condition. Many long-term glucocorticoid (GC) users never receive therapy to prevent bone loss or are…
Abstract Number: 2323 • 2018 ACR/ARHP Annual Meeting
Predictors of Mortality in Patients with Hip Fragility Fracture
Miguel Guerra¹, Sara Ganhão^2,3, Francisca Aguiar^2,3, Georgina Terroso², Romana Vieira¹, Diana Gonçalves⁴, Tiago Meirinhos⁵, Teresa Martins-Rocha^2,3, Ana Águeda^3,5, Raquel Ferreira^2,3, Miguel Bernardes^2,3, Carlos Vaz^2,3, Raquel Lucas⁶ and Lúcia Costa², ¹Rheumatology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, ²Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ³Faculty of Medicine, Oporto University, Oporto, Portugal, ⁴Rheumatology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ⁵Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁶Public Health Institute of Oporto University, Oporto, Portugal
Background/Purpose: In Osteoporosis, hip fractures account for significant disease burden, with increased morbi-mortality and financial load on the patient and healthcare system. This study aimed…
Abstract Number: 2326 • 2018 ACR/ARHP Annual Meeting
Outcomes One Year after Hip Fracture Repair in the Elderly: Does Social Isolation Matter?
Lisa A. Mandl¹, Serena Lian¹, Jackie Szymonifka², Kirsten Grueter³, Aidan Hadad³ and Joseph Lane³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Orthopaedic Surgery, Hospital for Special Surgery, New York, NY
Background/Purpose: Hip fractures are a serious public health issue with a significant population burden, especially among those over age 65. Social isolation—how integrated a patient…
Abstract Number: 2336 • 2018 ACR/ARHP Annual Meeting
Identification of Osteoporosis As a Reason for Vertebral Fractures in Patients with Rheumatoid Arthritis and Non-Inflammatory Musculoskeletal Diseases – a Comparison between Trabecular Bone Score (TBS) and Bone Mineral Density (BMD)
Bjoern Buehring¹, Xenofon Baraliakos¹, Julian Thomas² and Jürgen Braun¹, ¹Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany
Identification of osteoporosis as a reason for vertebral fractures in patients with rheumatoid arthritis and non-inflammatory musculoskeletal diseases – A comparison between trabecular bone score…
Abstract Number: 1144 • 2018 ACR/ARHP Annual Meeting
Risk of Osteoporotic Fractures in Patients with Rheumatoid Arthritis and End Stage Renal Disease. Findings from the Usrds Database
Renee Peterkin-McCalman, Jennifer Waller, Brian Le, Alyce Oliver, Evan Manning, Stanley Nahman and Laura Carbone, Medical College of Georgia at Augusta University, Augusta, GA
Background/Purpose: Rheumatoid arthritis (RA) and End Stage Renal Disease (ESRD) are independent risk factors for osteoporotic fractures. Approximately one percent of persons with ESRD have…
Abstract Number: 304 • 2017 ACR/ARHP Annual Meeting
Usefulness of Consecutive Doppler Ultrasound Examinations for Detecting Deep Venous Thrombosis during the Perioperative Period in Patients with Osteoporotic Fractures of the Proximal Femur
Ken Nakaseko and Norihiro Mayumi, Department of Orthopaedic Surgery and Rheumatology, Kuwana City Medical Center, Kuwana Mie, Japan
Background/Purpose: Deep venous thrombosis (DVT) can lead to a venous thromboembolism and increase the risk of a pulmonary thromboembolism (PE). PE is one of the…
Abstract Number: 1229 • 2017 ACR/ARHP Annual Meeting
Factors Affecting FRAX Score Calculation & Treatment in Practice
Avneet Vig¹, Beverly Johnson², Tony Francis³ and Barbara Mendez-Agrusa⁴, ¹Montefiore Medical Center, Bronx, NY, ²Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, ³Radiology, Albert Einstein College of Medicine, Bronx, NY, ⁴Medicine, Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Osteoporosis-related fractures causes increased disability and morbidity and mortality. The FRAX algorithm quantifies the 10 year probability of a hip or major osteoporotic fracture.…
Abstract Number: 2043 • 2017 ACR/ARHP Annual Meeting
Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
Brittany Frankel¹, Angela Christensen² and Monica Guma³, ¹Internal Medicine, University of California, San Diego, San Diego, CA, ²Rheumatology, University of California, San Diego, San Diego, CA, ³University of California, San Diego, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) 2010 guidelines recommend that any patient initiating glucocorticoid therapy with an anticipated duration of ≥3 months should receive a…
Abstract Number: 2379 • 2017 ACR/ARHP Annual Meeting
Effect of DKK-1 and Osteoprotegerin on Bone Mass in Tightly Controlled Rheumatoid Arthritis
Javier Narváez¹, Irene Martin-Esteve², Andrea Zacarias³, Pedro Alia⁴, Estibaliz Loza⁵, Loreto Carmona⁵, Joan Miquel Nolla² and Carmen Gomez Vaquero⁶, ¹Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitari de Bellvitge, Barcelona, Spain, ⁴Clinical Laboratory Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To analyze the association between osteoprotegerin (OPG) and Dickkopf-related protein 1 (DKK-1) and the annual percent change (Δ%) in bone mineral density (BMD) in patients…
Abstract Number: 333 • 2016 ACR/ARHP Annual Meeting
An Assessment of Bone Health and Fracture Risk in a Bariatric Surgery Population at an Urban Medical Center
Sherilyn Diomampo¹, Leila Muhieddine², Ann Igoe³, Charles Thomas⁴ and Sobia Hassan¹, ¹Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ²Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ³Medicine-Pediatrics, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ⁴Research, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Bariatric surgery is the most effective treatment for severe obesity.1,2 have been limited and conflicting reports as to the prevalence of osteoporosis and occurrence…
Abstract Number: 361 • 2016 ACR/ARHP Annual Meeting
The Effect of Immunosuppressive and Antiresorptive Therapy on Bone Mineral Density in Lung Transplant Patients
Mireia Barceló-Bru¹, Sandra Farietta-Varela², Basilio Rodriguez-Díez¹, Mireia López-Corbeto², Ernesto Trallero-Araguás¹, Juan Jose De Agustin De Oro², Roxana Coras² and Agusti Sellas-Fernandez², ¹Rheumatology, Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²Hospital Universitario Vall d´Hebron, Barcelona, Spain
Background/Purpose: Osteoporosis is a very frequent complication in recipients of a lung transplant . The factors that intervene can be previous to the transplant, such…
Abstract Number: 362 • 2016 ACR/ARHP Annual Meeting
Evaluation of Osteoporosis Risk Factors in Lung Transplant Patients
Sandra Farietta-Varela¹, Mireia Barceló-Bru², Basilio Rodriguez-Díez², Mireia López-Corbeto¹, Ernesto Trallero-Araguás², Juan Jose De Agustin De Oro¹, Roxana Coras¹ and Agusti Sellas-Fernandez¹, ¹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²Rheumatology, Hospital Universitario Vall d´Hebron, Barcelona, Spain
Background/Purpose: Patients with a terminal lung disease have a great number of risk factors for the development of osteoporosis. Although much has been learned about…
Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Masao Yukioka⁴, Takaaki Noguchi⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
Abstract Number: 1026 • 2016 ACR/ARHP Annual Meeting
Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Kenneth G. Saag¹, Tobie de Villiers², Peter Alexandersen³, Heidi Jacobe⁴, Carrie Kovarik⁵, Victoria P. Werth⁶, Albert Leung⁷, Avani Desai-Merchant⁸, Julie Mattaliano⁸ and Deborah Gurner⁸, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, Cape Town, South Africa, ³Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA, Philadelphia, PA, ⁷Formerly Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ⁸Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ
Background/Purpose: LOFT was a double-blind, placebo-controlled trial. Women ≥65 years with total hip (TH) or femoral neck (FN) bone mineral density (BMD) T-score ≤-2.5, or…
Abstract Number: 1160 • 2016 ACR/ARHP Annual Meeting
Development of a Shared Decision Making Tool for Osteoporosis Treatment
Sonam Kiwalkar, Internal Medicine, Rochester General Hospital, Rochester, NY
Background/Purpose: In this era of modern medicine, health care providers and patients are partners in making decisions about treatment. It is imperative that evidence-based medicine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.